Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck’s Vioxx Successor Arcoxia May Be Closer To Market

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA will need to weigh issues related to hypertension and length of the studies after preliminary results of massive trials show comparable cardiovascular events for etoricoxib and diclofenac.

You may also be interested in...



FDA Sets High Bar For Approval Of Merck’s COX-2 Arcoxia

FDA’s Arthritis Drugs Advisory Committee will review Merck’s Vioxx follow-on etoricoxib during an April 12 meeting.

FDA Sets High Bar For Approval Of Merck’s COX-2 Arcoxia

FDA’s Arthritis Drugs Advisory Committee will review Merck’s Vioxx follow-on etoricoxib during an April 12 meeting.

Complete MEDAL Data May Forge Arcoxia Approval

Clinical data presented by Merck is not qualitatively different from preliminary release of trial results for the COX-2 inhibitor.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel